Table 3.
Univariate analysis of GRP78 polymorphisms and clinical outcome in localized GA and locally advanced CRC
| Localized GA |
Locally advanced CRC |
|||||||
| Time to recurrence |
Overall survival |
Time to recurrence |
||||||
| n | Median, months (95% CI) | HR (95% CI) | Median, months (95% CI) | HR (95% CI) | n | Median, months (95% CI) | HR (95% CI) | |
| GRP78 rs391957 | ||||||||
| C/C | 63 | 7.0 (3.7–10.7a) | 1 | 7.3 (5.4–10.7a) | 1 | 88 | 12.2a (4.9–12.2a) | 1 |
| C/T | 56 | 1.6 (1.3–2.1) | 2.79 (1.56–4.97) | 3.8 (2.4–4.1) | 3.31 (1.65–6.62) | 97 | 9.4 (6.6–16.8a) | 1.01 (0.60–1.70) |
| T/T | 11 | 2.2 (0.8–4.9a) | 1.81 (0.67–4.91) | 4.9a (1.1–4.9a) | 2.25 (0.62–8.23) | 15 | 2.0 (1.4–5.4) | 2.61 (1.25–5.44) |
| P valueb | 0.001 | 0.002 | 0.015 | |||||
| C/T, T/Tc | 67 | 1.7 (1.3–2.2) | 2.61 (1.48–4.59) | 3.8 (2.8–4.5) | 3.17 (1.60–6.29) | |||
| P valueb | <0.001 | <0.001 | ||||||
| GRP78 rs17840761 | ||||||||
| A/A | 36 | 4.4 (2.5–10.7a) | 1 | 10.7a (4.5–10.7a) | 1 | 49 | 5.7 (3.5–12.2a) | 1 |
| A/G | 74 | 2.2 (1.7–12.3a) | 1.41 (0.73–2.72) | 4.1 (3.3–7.3) | 1.99 (0.87–4.55) | 126 | 10.7 (5.9–16.8a) | 0.87 (0.50–1.53) |
| G/G | 21 | 1.7 (0.8–7.0a) | 2.53 (1.12–5.69) | 3.8 (1.9–7.3a) | 3.24 (1.20–8.76) | 33 | 5.4 (2.0–12.4a) | 1.16 (0.58–2.31) |
| P valueb | 0.058 | 0.053 | 0.63 | |||||
| GRP78 rs12009 | ||||||||
| T/T | 55 | 3.2 (2.1–10.7a) | 1 | 5.4 (3.3–10.7a) | 1 | 62 | 5.7 (4.0–12.2a) | 1 |
| T/C | 58 | 2.1 (1.5–12.3a) | 1.26 (0.72–2.20) | 4.1 (2.8–12.3a) | 1.23 (0.64–2.38) | 116 | 10.7 (5.4–16.8a) | 0.88 (0.52–1.49) |
| C/C | 15 | 7.0 (1.1–7.0a) | 0.92 (0.37–2.26) | 4.7 (2.0–7.3a) | 1.19 (0.46–3.04) | 26 | 12.4a (1.5–12.4a) | 1.32 (0.65–2.68) |
| P valueb | 0.64 | 0.82 | 0.46 | |||||
a
Estimates were not reached.
b
Based on the log-rank test.
c
Dominant model.
GRP78, 78-kiloDalton glucose-regulated protein; GA, gastric adenocarcinoma; CRC, colorectal cancer; CI, confidence interval; HR, hazard ratio; CI, confidence interval.